<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219752</url>
  </required_header>
  <id_info>
    <org_study_id>020948</org_study_id>
    <secondary_id>CSTI571AFR04</secondary_id>
    <nct_id>NCT00219752</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years</brief_title>
  <official_title>Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase With Age More Than 70, Diagnosis of CML is Being Performed Within 1 Year</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in&#xD;
      patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis&#xD;
      of cml is being performed within 1 year. Quality of life will be carefully assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will received Imatinib at a dose of 400mg daily. Tolerability and quality of life&#xD;
      will be assessed Secondary objectives are : to evaluate the survival without progression, the&#xD;
      survival without event, the overall survival, the hematologic, cytogenetic and molecular&#xD;
      responses at various check points.&#xD;
&#xD;
      Duration of responses and failure to respond will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>. the survival without progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. the survival without event</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. the overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. the hematologic cytogenetic and molecular responses at various check points.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. duration of responses and failure to respond</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate 400 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CML Ph+ (assessed by cytogenetic or FISH)&#xD;
&#xD;
          -  Chronic phase with less than 5% bone marrow blasts&#xD;
&#xD;
          -  Diagnosis within 12 months&#xD;
&#xD;
          -  Age ≥ 70 year at inclusion&#xD;
&#xD;
          -  PS grade 0 to 2 (ECOG)&#xD;
&#xD;
          -  Mini mental status more than 25&#xD;
&#xD;
          -  Hydroxyurea optional before Imatinib&#xD;
&#xD;
          -  Adequate end organ function, defined as the following: total bilirubin &lt;1.5x uln, sgpt&#xD;
             &lt;3x uln, creatinine &lt;1.5x uln.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who cannot sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of this study in keeping with the policies of the hospital&#xD;
&#xD;
          -  Mini mental status ≤ 25&#xD;
&#xD;
          -  patients who are not able to adequately take the study drug&#xD;
&#xD;
          -  Age less than 70 y&#xD;
&#xD;
          -  accelerated or blastic phase&#xD;
&#xD;
          -  previous therapy with imatinib or interferon&#xD;
&#xD;
          -  HIV positivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François GUILHOT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers - FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe ROUSSELOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology and Oncology - University Hospital &quot;Saint Louis&quot; - 75475 PARIS cedex 10 (FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://lmc-cml.org/fr/</url>
    <description>French CML Group (FI-LMC) web-site</description>
  </link>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 21, 2005</last_update_submitted>
  <last_update_submitted_qc>December 21, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2005</last_update_posted>
  <keyword>CML - ederly patients - Imatinib mesylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

